NASDAQ:VCNXVaccinex Stock Price, Forecast & News

Vaccinex's stock was trading at $4.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCNX shares have decreased by 20.1% and is now trading at $3.33. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaccinex.

Vaccinex is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Vaccinex.

Vaccinex Inc (NASDAQ:VCNX) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.45) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.75) by $0.30. View Vaccinex's earnings history.

1 equities research analysts have issued 12 month price objectives for Vaccinex's shares. Their forecasts range from $22.00 to $22.00. On average, they anticipate Vaccinex's share price to reach $22.00 in the next year. This suggests a possible upside of 560.7% from the stock's current price. View analysts' price targets for Vaccinex.

News coverage about VCNX stock has trended negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vaccinex earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View the latest news about Vaccinex.

Some companies that are related to Vaccinex include XOMA (XOMA), Marinus Pharmaceuticals (MRNS), TAIWAN LIPOSOME/S (TLC), Lexicon Pharmaceuticals (LXRX), Mallinckrodt (MNK), LifeVantage (LFVN), Aduro BioTech (ADRO), Kezar Life Sciences (KZR), NeuBase Therapeutics (NBSE), Strongbridge Biopharma (SBBP), Chimerix (CMRX), Chiasma (CHMA), Alpine Immune Sciences (ALPN), Ritter Pharmaceuticals (RTTR) and Aravive (ARAV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include Agile Therapeutics (AGRX), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Exelixis (EXEL), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Opko Health (OPK), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Whiting Petroleum (WLL).

(VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCNX stock can currently be purchased for approximately $3.33.

Vaccinex has a market capitalization of $55.44 million and generates $520,000.00 in revenue each year. The company earns $-31,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Vaccinex employs 44 workers across the globe.

The official website for Vaccinex is www.vaccinex.com.

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]